Bisignano P , Ghezzi C , Jo H , Polizzi NF , Althoff T , Kalyanaraman C , Friemann R , Jacobson MP , Wright EM , Grabe M .

R01 GM089740 NIGMS NIH HHS

	Fig. 1. Predicted binding mode of phlorizin to hSGLT1 and hSGLT2. a Phlorizin bound to the outward-facing hSGLT1. The protein is gray, phlorizin is green and red, and Na+ at the putative Na2/Na3 sites are yellow. EL5c (red) is represented as cartoon. The 2D structures of phlorizin and phloretin are also shown. b Close-up view of phlorizin bound to hSGLT1. The sugar moiety occupies the sugar binding site aligning with the docked glucose (transparent yellow/red) where it makes excellent hydrogen bonding with the protein. The aglycon tail creates face-to-face aromatic π–π interactions with H83 and F101 and a cation–π interaction with R267 on EL5C. c Phloretin and glucose bound to hSGLT1. Phloretin (yellow/red) superposes over the aglycon tail from the phlorizin molecule (transparent green/red) in b, while glucose (yellow/red) aligns well with the sugar moiety. d Close-up view of phlorizin bound to hSGLT2. The binding mode is conserved in hSGLT2, although the aglycon tail is more tightly packed due to an aromatic cage that forms around the central ring made up of residues H80, F98, and H268 on EL5C
	Fig. 2. Predicted binding mode of dapagliflozin to hSGLT1 and hSGLT2. Dapagliflozin (orange/red) adopts a similar pose to phlorizin (transparent green/red) in both hSGLT1 (a) and hSGLT2 (b). Interactions in the sugar binding site and extracellular vestibule are preserved including the electrostatic interaction with R267 (hSGLT1) and the aromatic cage formed by H80, F98, and H268 (hSGLT2). c αMDG hSGLT1 D268H (black squares) sugar currents. αMDG currents were measured at Vm = −50mV. The red dashed curve is a representative, wild-type hSGLT1 response. For the D268H mutant K0.5 = 1.2 ± 0.1 mM, while wild-type hSGLT1 K0.5 = 0.9 ± 0.1 mM. For c and d, data are normalized to the current measured at 10 mM αMDG. d Na+ dependence of αMDG currents measured in 10 mM αMDG at Vm = −50mV. For hSGLT1 D268H K0.5 = 17 ± 1.2 mM and for wild-type hSGLT1 K0.5 = 36 ± 1 mM. Hill coefficients hSGLT1 D268H and wild-type were 1.62 ± 0.03 and 1.61 ± 0.1. e Phlorizin and f dapagliflozin effect on the Qmax for hSGLT1 D268H, we estimated a Ki = 0.3 ± 0.1 and 0.035 ± 0.011 µM for phlorizin and dapagliflozin, respectively, while the wild-type Ki = 0.22 ± 0.04 and 0.45 ± 0.02 µM. For c–f, each data point is the mean ± SEM of n ≥ 5 oocytes
	Fig. 3. Outer gate closure explains the impact of TM9-10 residues on substrate binding. a The outer gate residue Q457 on TM10 does not interact with phlorizin (green/red) in the outward-facing model of hSGLT1. b A molecular dynamics simulation of the hSGLT1–phlorizin complex reveals significant movement in the TM9-10 outer gate bringing Q457 into direct contact with phlorizin. Additionally, EL5C (red) closes over the top of the inhibitor. This figure is a snapshot from the trajectory at 1 μs. Lipids and water are not shown for clarity
	Fig. 4. Allosteric communication between sodium and substrate sites. a The hSGLT1–phlorizin model shows the location of Na+ (transparent yellow) in the Na2 site over 8 à from the inhibitor and the putative Na3 site 14 à away. The Na2 Na+ interacts with the side chains of S392 and S393 and the carbonyl backbone of I79, while the ion at Na3 is stabilized by backbone carbonyls, side chains of T395 and S396, and bidentate interaction with D204. b The hSGLT2–phlorizin model shows the location of the conserved Na2 binding site (transparent yellow), but the putative Na3 site is lost by the hydrophobic substitution A395. c hSGLT1 T395A and wild-type hSGLT1 and hSGLT2 stoichiometries were determined from the reversal potential (Vrev). The inverse of the slope, Na+-to-glucose coupling ratio, n, is 1-to-1 Na+-to-substrate stoichiometry for the hSGLT2 wild-type and the T395A hSGLT1 mutant and 2-to-1 for wild-type hSGLT1. d αMDG dependence of hSGLT1 T395A (black squares) sugar current in injected oocytes. K0.5 = 34 ± 4 mM compared to K0.5 = 0.9 ± 0.1 mM for wild type. Data in d–f are normalized to the current measured in 10 mM αMDG without inhibitors, and the red dashed curves are representative, wild-type hSGLT1 responses. e Phlorizin (black squares) and dapagliflozin (open squares) effect on αMDG currents for hSGLT1 T395A in 30 mM αMDG. For hSGLT1 T395A Ki = 0.35 ± 0.10 and 0.4 ± 0.1 µM for phlorizin and dapagliflozin, respectively, while wild type estimated Ki = 0.22 ± 0.04 and 0.45 ± 0.02 µM for phlorizin and dapagliflozin, respectively. f Phloretin (black circles) and dapa-aglycon (open circles) effect on αMDG currents for hSGLT1 T395A in 30 mM αMDG. For hSGLT1 T395A Ki = 20 ± 7 and 187 ± 80 µM for phloretin and dapa-aglycon, respectively, while the wild-type Ki = 55 ± 12 and 425 ± 50 µM for phloretin and dapa-aglycon, respectively. Each data point is the mean ± SEM of n = 10 oocytes (c), n ≥ 5 oocytes (d), and n ≥ 7 oocytes (e, f)
	Fig. 5. Allosteric model of inhibitor binding to SGLTs. The binding of phlorizin-like inhibitors to the outward-facing state of SGLTs leads to a partial closure of the TM9-10 outer gate in an induced fit mechanism. a, c Binding of 2 Na+ to hSGLT1 stabilizes the outer gate in an open conformation making it less favorable for the gate to close over the aglycon tails of inhibitors. b, d The absence of the Na3 site in hSGLT2 makes partial closure and inhibitor binding more favorable and therefore the inhibitors more potent. Additionally, elements of EL5C (red) contribute to better binding to hSGLT2

Adelman, Stochastic steps in secondary active sugar transport. 2016, Pubmed

Adelman, Stochastic steps in secondary active sugar transport. 2016, Pubmed
Bakan, ProDy: protein dynamics inferred from theory and experiments. 2011, Pubmed
Berman, The Protein Data Bank. 2000, Pubmed
Braun, Calculation of protein conformations by proton-proton distance constraints. A new efficient algorithm. 1985, Pubmed
Claxton, Ion/substrate-dependent conformational dynamics of a bacterial homolog of neurotransmitter:sodium symporters. 2010, Pubmed
Coady, MAP17 Is a Necessary Activator of Renal Na+/Glucose Cotransporter SGLT2. 2017, Pubmed , Xenbase
Coady, Characterization of the transport activity of SGLT2/MAP17, the renal low-affinity Na+-glucose cotransporter. 2017, Pubmed , Xenbase
Dickson, Lipid14: The Amber Lipid Force Field. 2014, Pubmed
Eswar, Comparative protein structure modeling using Modeller. 2006, Pubmed
Faham, The crystal structure of a sodium galactose transporter reveals mechanistic insights into Na+/sugar symport. 2008, Pubmed
Friesner, Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. 2006, Pubmed
Friesner, Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. 2004, Pubmed
Gallo, Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences. 2015, Pubmed
Ghezzi, SGLT2 inhibitors act from the extracellular surface of the cell membrane. 2014, Pubmed
Gorraitz, Active site voltage clamp fluorometry of the sodium glucose cotransporter hSGLT1. 2017, Pubmed , Xenbase
Harder, OPLS3: A Force Field Providing Broad Coverage of Drug-like Small Molecules and Proteins. 2016, Pubmed
Harding, Metal-ligand geometry relevant to proteins and in proteins: sodium and potassium. 2002, Pubmed
Hediger, Homology of the human intestinal Na+/glucose and Escherichia coli Na+/proline cotransporters. 1989, Pubmed
Hoover, Canonical dynamics: Equilibrium phase-space distributions. 1985, Pubmed
Hummel, Structural selectivity of human SGLT inhibitors. 2012, Pubmed
Hummel, Glucose transport by human renal Na+/D-glucose cotransporters SGLT1 and SGLT2. 2011, Pubmed
Jiang, The importance of being aromatic: π interactions in sodium symporters. 2012, Pubmed , Xenbase
Jo, Automated builder and database of protein/membrane complexes for molecular dynamics simulations. 2007, Pubmed
Joung, Determination of alkali and halide monovalent ion parameters for use in explicitly solvated biomolecular simulations. 2008, Pubmed
Kazmier, Conformational cycle and ion-coupling mechanism of the Na+/hydantoin transporter Mhp1. 2014, Pubmed
Klauda, Update of the CHARMM all-atom additive force field for lipids: validation on six lipid types. 2010, Pubmed
Koshy, Structural evidence for functional lipid interactions in the betaine transporter BetP. 2013, Pubmed
Krishnamurthy, X-ray structures of LeuT in substrate-free outward-open and apo inward-open states. 2012, Pubmed
Li, The VSGB 2.0 model: a next generation energy model for high resolution protein structure modeling. 2011, Pubmed
Lomize, OPM: orientations of proteins in membranes database. 2006, Pubmed
Loo, Functional identification and characterization of sodium binding sites in Na symporters. 2013, Pubmed
Loo, Conformational dynamics of hSGLT1 during Na+/glucose cotransport. 2006, Pubmed , Xenbase
Maier, ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SB. 2015, Pubmed
Meng, Tools for integrated sequence-structure analysis with UCSF Chimera. 2006, Pubmed
Mudaliar, Sodium-Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport: From Bench to Bedside. 2015, Pubmed
Myers, Optimal alignments in linear space. 1988, Pubmed
Ng, Concise and Stereodivergent Synthesis of Carbasugars Reveals Unexpected Structure-Activity Relationship (SAR) of SGLT2 Inhibition. 2017, Pubmed
Olsson, PROPKA3: Consistent Treatment of Internal and Surface Residues in Empirical pKa Predictions. 2011, Pubmed
Paz, Conformational transitions of the sodium-dependent sugar transporter, vSGLT. 2018, Pubmed
Perez, Alternating-access mechanism in conformationally asymmetric trimers of the betaine transporter BetP. 2012, Pubmed
Pettersen, UCSF Chimera--a visualization system for exploratory research and analysis. 2004, Pubmed
Sala-Rabanal, Bridging the gap between structure and kinetics of human SGLT1. 2012, Pubmed , Xenbase
Salomon-Ferrer, Routine Microsecond Molecular Dynamics Simulations with AMBER on GPUs. 2. Explicit Solvent Particle Mesh Ewald. 2013, Pubmed
Scholl-Bürgi, Long-term outcome of renal glucosuria type 0: the original patient and his natural history. 2004, Pubmed
Shen, Statistical potential for assessment and prediction of protein structures. 2006, Pubmed
Sherman, Novel procedure for modeling ligand/receptor induced fit effects. 2006, Pubmed
Shimamura, Molecular basis of alternating access membrane transport by the sodium-hydantoin transporter Mhp1. 2010, Pubmed
Wahlgren, Substrate-bound outward-open structure of a Na+-coupled sialic acid symporter reveals a new Na+ site. 2018, Pubmed
Wang, Automatic atom type and bond type perception in molecular mechanical calculations. 2006, Pubmed
Wang, Development and testing of a general amber force field. 2004, Pubmed
Watanabe, The mechanism of sodium and substrate release from the binding pocket of vSGLT. 2010, Pubmed
Wells, Cloning of a human kidney cDNA with similarity to the sodium-glucose cotransporter. 1992, Pubmed , Xenbase
Weyand, Structure and molecular mechanism of a nucleobase-cation-symport-1 family transporter. 2008, Pubmed
Word, Visualizing and quantifying molecular goodness-of-fit: small-probe contact dots with explicit hydrogen atoms. 1999, Pubmed
Wright, The sodium/glucose cotransport family SLC5. 2004, Pubmed
Wright, Biology of human sodium glucose transporters. 2011, Pubmed
Yamashita, Crystal structure of a bacterial homologue of Na+/Cl--dependent neurotransmitter transporters. 2005, Pubmed
Zhang, Structural elements required for coupling ion and substrate transport in the neurotransmitter transporter homolog LeuT. 2018, Pubmed
Zhao, Synthesis of phenol, aromatic ether, and benzofuran derivatives by copper-catalyzed hydroxylation of aryl halides. 2009, Pubmed
Zinman, Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. 2015, Pubmed